Announcements Trials
Browse Landscape

Phase

Phase NA 2Phase 2 2Phase 3 1Phase 1 1

Status

Completed 9Terminated 2Unknown 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2

Conditions

Breast Neoplasms 413Carcinoma, Non-Small-Cell Lung 286Prostatic Neoplasms 208Neoplasms 204Neoplasm Metastasis 180Melanoma 164Multiple Myeloma 158Colorectal Neoplasms 158Leukemia, Myeloid, Acute 143Lung Neoplasms 132Leukemia 126Lymphoma 118Pancreatic Neoplasms 117Recurrence 111Ovarian Neoplasms 111Leukemia, Lymphocytic, Chronic, B-Cell 110Lymphoma, Non-Hodgkin 105Carcinoma, Renal Cell 104Brain Neoplasms 90Myelodysplastic Syndromes 88Precursor Cell Lymphoblastic Leukemia-Lymphoma 86Glioblastoma 85Lymphoma, Large B-Cell, Diffuse 80Lymphoma, Follicular 79Carcinoma, Hepatocellular 79Head and Neck Neoplasms 77Squamous Cell Carcinoma of Head and Neck 76Urinary Bladder Neoplasms 66Stomach Neoplasms 61Hodgkin Disease 60

Interventions

Paclitaxel 2emactuzumab 1Taxes 1Surgical Procedures, Operative 1Immunoglobulin G 1Disulfides 1Cytoreduction Surgical Procedures 1Carboplatin 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Terminated × Brenner Tumor × Clear all
NCT02923739 2024-03-13

Paclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

M.D. Anderson Cancer Center

Phase 2 Terminated
9 enrolled 9 charts
Gynecologic

Brenner Tumor, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT00331422 2017-12-28

Carboplatin, Paclitaxel, and Surgery in Treating Patients With Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer

Masonic Cancer Center, University of Minnesota

Phase 2 Terminated
7 enrolled 8 charts
Gynecologic

Carcinoma, Ovarian Epithelial, Brenner Tumor, Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡